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Abstract
Background There is currently no consensus in the lit-
erature on which embolic agent induces the greatest degree
of liver hypertrophy after portal vein embolization (PVE).
Only experimental results in a pig model have demon-
strated an advantage of n-butyl-cyanoacrylate (NBCA)
over 3 other embolic materials (hydrophilic gel, small and
large polyvinyl alcohol particles) for PVE. Therefore, the
aim of this human study was to retrospectively compare the
results of PVE using NBCA with those using spherical
microparticles plus coils.
Methods A total of 34 patients underwent PVE using
either NBCA (n = 20), or spherical microparticles plus
coils (n = 14). PVE was decided according to preoperative
volumetry on the basis of contrast-enhanced CT. Groups
were compared for age, sex, volume of the left lobe before
PVE and future remnant liver ratio (FRL) (volume of the
left lobe/total liver volume - tumor volume). The primary
end point was the increase in left lobe volume 1 month
after PVE. Secondary end points were procedure compli-
cations and biological tolerance.
Results Both groups were similar in terms of age, sex ratio,
left lobe volume, and FRL before PVE. NBCA induced a
greater increase in volume after PVE than did microparticles
plus coils (respectively, ?74 ± 69 % and ?23 ± 14 %,
p \ 0.05). The amount of contrast medium used for the pro-
cedure was significantly larger when microparticles and coils
rather than NBCA were used (respectively, 264 ± 43 ml and
162 ± 34 ml, p \ 0.01). The rate of PVE complications as
well as the biological tolerance was similar in both groups.
Conclusion NBCA seems more effective than spherical
microparticles plus coils to induce left-lobe hypertrophy.
Keywords Comparative study  Embolic material 
Embolization  Liver regeneration  Portal vein
Introduction
Since the first report of portal-branch ligation to induce
hypertrophy of the contralateral liver lobe in rabbits in
1920 [1] and the first use of portal vein embolization (PVE)
in clinical practice in 1986 by Kinoshita et al. [2], many
techniques of portal vein occlusion have been described
[3]. Various embolic materials have been proposed for the
complete occlusion of the right portal branches both
proximally and distally thereby preventing recanalization
of the portal vein or collateralization from the left side
[4, 5]. American studies [6] have mainly reported embo-
lization using spherical particles associated with proximal
coils, while European groups mainly use n-butyl-cyano-
acrylate (NBCA) mixed with iodized oil [7, 8]. Experi-
mental results in a pig model [9] have demonstrated the
advantage of NBCA over three other embolic materials
(hydrophilic gel, and small and large polyvinyl alcohol
particles), the second best embolic material being small
(50–150 lm) particles. However, to our knowledge, this
result has never been confirmed in a human study. Thus,
the objective of this study was to compare two consecutive
groups of patients selected according to the same criteria
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by the same surgical and radiological team, and embolized
with either NBCA or microparticles plus coils.
Materials and Methods
This study consisted of a retrospective analysis of two
consecutive groups of patients. All patients gave their
written informed consent for the procedure and our local
ethics committee approved the retrospective analysis of
their data.
All consecutive patients selected for right PVE were
included in this study. Between January 2010 and October
2010, the first 14 patients, with a median age of 69 (range
52–74) years, underwent right PVE using spherical micro-
particles plus coils as described by Madoff and coll. [10].
Five patients had HCC developed on liver cirrhosis, while
eight had liver metastases and one had intrahepatic cholan-
giocarcinoma (Table 1). Between November 2010 and
January 2012, the next 20 patients, with a median age of 68.5
(range 46–79) years, underwent right PVE using NBCA.
Seven patients had hepatocellular carcinoma (HCC) devel-
oped from liver cirrhosis, while 13 patients had liver
metastases (Table 1). No patient had undergone prior ther-
apy such as transarterial chemoembolization or systemic
chemotherapy.
Inclusion and Exclusion Criteria
All of the patients gave their written informed consent.
Patients with liver metastases developed on a healthy liver
were considered for right PVE if the planned resection
would have left less than 30 % of functional liver paren-
chyma estimated on liver volumetry measured by CT before
surgery. All of the patients with hepatocellular carcinoma
developed on cirrhosis were considered for PVE if right
hepatectomy was planned. Patients with HCC developed on
cirrhosis were eligible for right hepatectomy if the HCC
was located in the right lobe, if they had Child Pugh grade A
cirrhosis, if there was no evidence of extrahepatic disease,
if the portal and hepatic veins and bile ducts were patent,
and if they were less than 75 years-old. In our center, PVE
was not considered if patients had extrahepatic tumors,
Child-Pugh grade B or C cirrhosis, trans-arterial chemo-
embolization in the previous 3 months, signs of active
alcoholic hepatitis, serum alanine aminotransferase levels
more than twice the normal values [11], or if they were
being treated with interferon therapy. Patients considered
for embolization of the right portal branches plus segment
IV branches were not included in this study.
The decision to treat (right PVE and liver resection) was
taken at the weekly liver tumor board meeting. The board
included liver surgeons, oncologists, hepatologists, and
interventional radiologists. For all of the patients included
in this study right hepatectomy for the removal of segments
V, VI, VII and VIII had been planned.
Technique of PVE
PVE was performed under general anesthesia by an inter-
ventional radiologist with 15 years of experience in inter-
ventional liver procedures, during a 48 h hospital stay. PVE
using NBCA was performed according to the technique
previously described by De Baere et al. [7]: A left portal vein
branch (preferentially a segment III branch) was punctured
under sonographic guidance using a 30 cm long 5F Ring
needle catheter (Cook, Bloomington, IN, USA) and portal
pressure was measured. The Ring catheter was advanced
over a 0.035-inch hydrophilic guide wire (Terumo, Tokyo,
Japan) into the portal trunk where portography was per-
formed. The right second-order portal branches were selec-
tively catheterized one by one using the ring catheter and
then embolized with boluses of 0.5 ml of a mixture of
Lipiodol and n-butyl-cyanoacrylate (Histoacryl, B Braun,
Tuttlingen, Germany) after checking that the flow was hep-
atopetal (a mixture of 1 ml of n-butyl cyanoacrylate with
1–3 ml of iodized oil was used). Dilution of the NCBA and
Lipiodol was adapted to the portal venous flow so that both
distal and proximal branch occlusion could be achieved. In
case of rapid flow (as usually observed at the beginning of the
Table 1 Comparison of baseline characteristics of patients receiving PVE using NBCA or microparticles plus coils
Characteristic NBCA Microparticles plus coils p
(n = 20) (n = 14)
Age, mean ± SD 68 ± 12 67 ± 9 [0.05
Sex ratio, F/M 6/14 5/9 [0.05
Cirrhosis/metastases 7/13 5/9 [0.05
Total liver volume, ml, mean ± SD 1978 ± 1352 1692 ± 391 [0.05
Left lobe volume, ml, mean ± SD 470 ± 210 495 ± 191 [0.05
FRL ratio, mean ± SD 0.27 ± 0.11 0.29 ± 0.06 [0.05
PVE portal vein embolization, NBCA n-butyl-cyanoacrylate, SD standard deviation, FRL future remnant liver
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embolization), dilution with a ratio of NCBA/lipiodol of 1:2
was used. In case of reduced portal flow, a dilution of 1:1 was
used to avoid the migration of the embolic agent into the left
branches. To reduce this risk, NBCA was injected selectively
into the segmental branches. After embolization, the Ring
catheter was carefully flushed in the right portal branch with
5 % glucose solution and then repositioned in the portal
trunk, where post-PVE portography was performed and
portal pressure was measured.
PVE using microparticles plus coils was derived from the
technique described by Madoff et al. [6]. We decided to use
small spherical particles after the results of an experimental
study in pig [9]. We used the same portal approach and the
same Ring catheter as for NBCA PVE. Embolization was
achieved with 100–300 lm spherical particles injected
selectively into the distal portal branches (Bead Block,
Terumo, Japan). A 1:1 dilution was used between particles and
contrast media as recommended by Terumo. Once stasis had
been achieved with microparticles in the peripheral branches,
0.035-inch coils (Tornado; Cook) were also placed proximally
in order to occlude the origin of the right portal branches. For
all procedures, portal pressure was measured before and at the
end of the embolization procedure. The amount of contrast
medium injected was recorded for each procedure.
Volumetric CT Assessment and Outcome Evaluation
Baseline computed tomography (CT) imaging data were
obtained a mean of 8 (range 1–21) days before PVE, and
follow-up imaging was performed a mean of 30 (range 25–35)
days after PVE. CT images with a 2.5 mm slice thickness were
obtained during the portal phase (70 s after injection of
100 ml of 350 lg/ml iodine at 3 ml/s) after injection of con-
trast media with a 16-detector row Lightspeed multislice CT
unit (General Electric, Milwaukee, WI, USA) as previously
described [12, 13]. On each image, the whole liver, the tumor
and the left lobe (segments II, III, and IV) were delineated with
a handheld cursor [14] and their respective volumes were
automatically calculated by the workstation (Advantage
Windows; General Electric). Depending on the vascular
anatomy of the liver, the delineation of the right and left lobes
was defined by the plane between the gallbladder fossa and the
middle hepatic vein to the inferior vena cava. Total functional
liver volume (TLV) was defined as the total liver volume
minus the tumor volume. The ratio between the left lobe
volume and the TLV was then calculated and defined as the
future remnant liver ratio (FRL).
Biological Changes after PVE
Serum liver enzymes were assessed by measuring serum
aspartate amino transferase (AST), prothrombin time (PT)
and total bilirubin levels before and 1 month after PVE.
Study End Points
The primary end point of the study was to compare left lobe
volume and FRL increase after PVE using microparticles plus
coils vs. NBCA. Secondary end points were comparison of
patient outcome, biological changes and portal pressure
modifications after PVE in the two groups. We also compared
the amount of embolic material necessary to obtain PVE in
metastatic vs. HCC patients in each group. Finally, we com-
pared the amount of contrast medium used for the procedures.
Statistical Analysis
The volumetric results are reported as means ± standard
deviations unless stated otherwise. The normal distribution
of variables was checked using the Shapiro–Wilk test.
When variables did not have a normal distribution, a Mann–
Whitney test was applied for comparison. Comparisons of
FRL and left liver volumes, portal pressures, and laboratory
tests before and 1 month after PVE were performed by a
paired t test. Comparison between the two groups was
performed by Fisher’s test and an unpaired t test. A p value
of \ 0.05 was considered statistically significant.
Statistical analysis was performed by JMP software
(SAS Institute, Cary, NC, USA).
Results
The groups receiving NBCA or spherical particles were
similar in terms of age, sex ratio, the proportion of cirrhotic
patients, left lobe volume and FRL before PVE (Table 1).
PVE was achieved in all patients. No complication related
to the procedure was observed during this study in either
group. At the 1 month follow-up CT, imaging revealed that
one patient had small fragments of NBCA in distal left portal
branches without compromising the patency of proximal and
segmental portal vein branches.
Embolization using microparticles required a mean number
of 10.3 ± 3.4 vials of 100–300 lm particles. In HCC patients,
the amount of embolic material per patient was significantly
less than that necessary to achieve PVE in metastatic patients
(7.6 ± 2.7 vs. 11.77 ± 2.9 vials, respectively, p\ 0.05). The
number of coils per patient was similar in these two categories
of patients. The amount of contrast medium used for the pro-
cedure was 264 ± 43 ml and 162 ± 34 ml, for microparticles
plus coils and NBCA, respectively (p\ 0.01). No renal dys-
function was observed in either group.
Volumetric Efficacy
After PVE, the left lobe increased in size from 495 ± 191 ml
to 600 ± 198 ml with microparticles plus coils and from
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470 ± 210 ml to 682 ± 173 ml with NBCA, leading to a
left lobe increase in size of 23 ± 14 % and 74 ± 69 %
(p = 0.046), respectively (Figs. 1, 2, 3). The increase in the
FRL ratio was 29 ± 16 % and 48 ± 36 % for patients
embolized with microparticles plus coils and NBCA,
respectively (p = 0.07).
Biological Changes, Portal Pressures, and Patient
Outcome
Serum levels of liver enzymes did not significantly differ
before and 1 month after PVE. No significant differences
were found between the two groups (Table 2). The increase
in portal pressure measured after PVE did not significantly
differ in the group microparticles plus coils vs. NBCA:
2.9 ± 1.3 mm Hg and 3.2 ± 1.2 mm Hg, respectively.
In the NBCA group, 15 (75 %) of the 20 patients
underwent right hepatectomy. Three patients had tumor
progression, which precluded resection. One HCC patients
developed extrahepatic metastases that were not visible on
the first evaluation, and during the operation one patient
was found to have peritoneal carcinomatosis. In the
microparticles plus coils group, 11 (78.6 %) patients under-
went surgical resection, 10 by right hepatectomy and one
by multiple nonanatomic resections. Three patients were
not operated on: one HCC patient because of additional
nodules found in the left lobe; one HCC patient with Child-
Pugh A cirrhosis because of an insufficient increase in left
lobe volume after PVE; and one patient because of peri-
toneal extension of the sigmoid cancer discovered during
laparotomy.
Fig. 1 Portography before (A) and after (B) PVE using NBCA in a
64-year-old patient with HCC
Fig. 2 Portography before (A) and after (B) PVE using microparti-
cles plus coils in a 73-year-old patient with liver metastases from
sigmoid cancer
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Discussion
Different embolic materials have been proposed for PVE. In
the initial study of Makuushi et al., a gelatin sponge mixed
with diatrizoate sodium meglumine and gentamycin was
used [15]. However, frequent recanalizations were observed
after embolization, and these required additional proce-
dures. Ogasawara et al. reported the use of absolute alcohol
injected through an occlusion balloon into the right lobe
[16]. This technique seemed very efficient in terms of
hypertrophy, but was poorly tolerated especially in patients
with chronic liver disease in whom major changes in liver
function may preclude surgery. Finally, most American and
European teams use either a combination of microparticles
plus coils [6] or a mixture of NBCA and iodized oil [7, 8,
17]. Although these two techniques have produced good
results in clinical practice and may seem similar in terms of
results and complications [18], they are difficult to compare
using data from the literature. As recently reported in a
meta-analysis, it is impossible to determine the best embolic
agent for PVE [3]. Series cannot be compared easily
because of different case mixes of liver metastases [6, 19]
and hepatocellular carcinoma [8, 20, 21], because of dif-
ferent delays (from 2 weeks [20] to 5 weeks [8]) for the
volumetric assessment, or even because patients received
associated techniques like chemoembolization, which affects
regeneration [22]. More importantly, the degree of hyper-
trophy of the FRL was not measured in the same way in the
different series [23]. Indeed, some authors assessed hyper-
trophy by comparing the ratio of the left lobe volume divided
by the total measured liver volume minus the tumor volume
before and 1 month after PVE. However, this volumetric end
point may be influenced by an increase in left lobe volume,
by a decrease in embolized liver volume, or by both mech-
anisms. Authors who used microparticles plus coils divided
the left lobe volume by an estimated total liver volume. This
estimation was derived from a formula based on body surface
area to give a theoretical total liver volume [12], which
although simple to obtain, cannot reflect true liver volume in
all cases.
Therefore, we decided to compare different embolic
agents for PVE both experimentally and clinically in
reproducible conditions. The present study demonstrated
that a greater degree of liver hypertrophy was achieved with
NBCA than with microparticles plus coils. This result is in
keeping with the results observed in an experimental work
[9] comparing various embolic materials for PVE in a pig
model. In this animal study, hypertrophy of the nonem-
bolized liver was evaluated histologically and on the basis
of liver lobe surface area measurements. It was demon-
strated that NBCA was better able to induce liver hyper-
trophy than were small 50–150 lm nonspherical particles,
which in turn were better than large (500–700 lm) spheri-
cal particles. Because it has been reported that very small
particles, below 100 lm, are dangerous for use in arterial
embolization of the liver because they might induce fatal
pulmonary embolization of small distal pulmonary arteries
[24], we decided to use 100–300 lm spherical particles in
our clinical study. With this size of particles, no pulmonary
complications after PVE have ever been reported [3]. In the
experimental study in pig, the ratio of surface areas of liver
lobules in the nonembolized vs. embolized liver was 40 %
higher for NBCA than for small particles. We found a
similar picture in this clinical study in terms of FRL
Fig. 3 Graph showing the mean ± SD increase in left lobe volume
1 month after PVE using NBCA and microparticles plus coils
Table 2 Biological tests before PVE and surgery in the NBCA group and in the microparticles plus coils group
Characteristic NBCA, mean ± SD Microparticles plus coils, mean ± SD p
Total bilirubin before PVE, lmol/L 12 ± 4 12 ± 4 [0.05
Total bilirubin before surgery, lmol/L 13 ± 5 13 ± 3 [0.05
AST before PVE, U/L 34 ± 12 31 ± 13 [0.05
AST before Surgery, U/L 36 ± 13 32 ± 14 [0.05
PT before PVE, U/L 88 ± 7 90 ± 6 [0.05
PT before surgery, U/L 86 ± 9 87 ± 7 [0.05
In both groups, total bilirubin, AST, and PT values before PVE did not significantly differ from their values before surgery
PVE portal vein embolization, NBCA n-butyl-cyanoacrylate, SD standard deviation, AST aspartate aminotransferase, PT prothrombin time
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hypertrophy measured by CT volumetry when NBCA was
compared with spherical 100–300 lm particles plus coils.
One explanation for the better results of NBCA could be the
inflammatory reaction observed in the periportal area as
mentioned in a previous publication [7] as well as in the
animal study [9]. Indeed, the present study strongly sug-
gests that the mechanical effect of portal precapillary
occlusion is probably not the only mechanism involved in
the regeneration phenomenon as suggested by complete
right portal vein occlusion and a similar increase in portal
vein pressure after PVE in both groups.
We found no differences between the two groups in
terms of resection rate after PVE. Our resection rate of
76 % is close to the resection rate of 85 % reported by
Abulkhir et al. in a meta-analysis of 1088 patients [3]. We
encountered neither renal dysfunction nor side effects
related to the contrast medium, but it is noteworthy that we
used almost twice as much contrast medium with micro-
particle plus coil embolization than with NBCA emboli-
zation. This may have a potential impact mainly in patients
with HCC developed on cirrhosis because these patients
are more likely to develop hepatorenal syndrome. Although
we did not specifically assess the cost of the two proce-
dures, PVE using large quantities of microparticles toge-
ther with the coils is likely to be more costly than PVE
using only NBCA.
This study has several limitations, including its retro-
spective design, the small number of patients in each
group, and the use of historical controls [25] rather than a
randomized trial. However, the baseline characteristics of
the groups did not significantly differ, and the statistically
significant difference in the increase in left lobe volume
confirmed the histological results observed in a pig model.
In conclusion, the results of this clinical series confirm the
results obtained in our own experimental study. Although
both techniques induced complete occlusion of the portal
branches, NBCA seems to induce a greater degree of liver
hypertrophy. The periportal inflammation observed with
NBCA in the experimental study seems to be an important
factor for liver regeneration.
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